Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 (iparomlimab + tuvonralimab) plus paclitaxel/carboplatin as neoadjuvant therapy for advanced ovarian cancer with high CD8+ TILs
ChiCTR2500113846Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Percentage of CRS 3. Started Dec 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2500113846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113846.